Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait

Abrilada May Launch From Late 2023 Under A Settlement With AbbVie

 
• By David Wallace
  
Pfizer
Pfizer has received an FDA nod for its Abrilada adalimumab biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products